Kineta, Inc.

Equities

KA

US49461C1027

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 07:23:59 18/06/2024 pm IST			5-day change	1st Jan Change
0.4914 ^USD	-8.99%		+10.28%	-86.23%

15/05	Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/04	Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	CI

Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 16, 2024 at 01:36 am IST

Kineta, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 10.24 million compared to USD 6.45 million a year ago. Basic loss per share from continuing operations was USD 0.89 compared to USD 0.77 a year ago.

Latest news about Kineta, Inc.

Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	09/04	CI
Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	22/03	MT
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123	12/03	CI
Top Midday Decliners	01/03	MT
Kineta, Inc. Terminates Employment of Pauline Kenny as General Counsel and Secretary	29/02	CI
Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO	29/02	CI
Kineta, Inc. Announces Restructuring and Workforce Reduction	29/02	CI
Kineta Announces Exploration of Strategic Alternatives	29/02	CI
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity	17/01	CI
Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting	06/11	CI
Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors	17/23/17	CI
Kineta Closes $3 Million Offering of Common Stock	06/23/06	MT
Sector Update: Health Care Stocks Advancing Late Afternoon	05/23/05	MT
Sector Update: Health Care Stocks Lower Wednesday Afternoon	04/23/04	MT
Kineta Prices $3 Million Registered Direct Offering of Common Stock; Shares Down Pre-Bell	04/23/04	MT
Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial	03/23/03	CI
Earnings Flash (KA) KINETA Posts Q2 Revenue $5.2M	12/23/12	MT
Kineta Says It Is Set to Receive $5 Million Milestone Payment From Merck	29/23/29	MT
Kineta, Inc. Announces Board Appointments	28/23/28	CI
Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Earnings Flash (KA) KINETA Posts Q1 Revenue $281,000	12/23/12	MT
HC Wainwright Starts Kineta at Buy With $8 Price Target	01/23/01	MT
Top Premarket Decliners	28/23/28	MT
Kineta Closes $6 Million Registered Direct Offering	25/23/25	MT

Chart Kineta, Inc.

Duration

Period

More charts

Company Profile

Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.

Sector

Biotechnology & Medical Research

Calendar

22/06/2024 - Annual General Meeting

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KINETA, INC.	-86.46%	6.62M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+19.11%	113B
ARGENX SE	+2.56%	22.66B
BIONTECH SE	-16.35%	21.34B
WUXI APPTEC CO., LTD.	-39.57%	16.92B
BEIGENE, LTD.	-13.93%	16.68B
GENMAB A/S	-16.22%	16.61B
NEUROCRINE BIOSCIENCES, INC.	+3.01%	13.62B
SAREPTA THERAPEUTICS, INC.	+21.82%	11.04B

Bio Therapeutic Drugs

Kineta, Inc.

Equities

KA

US49461C1027

Biotechnology & Medical Research

Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

Latest news about Kineta, Inc.

Chart Kineta, Inc.

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs